These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28632424)

  • 1. The progress in the research of antiplatelet agents (1995-2017).
    Benimana O; Zhao L; Kong Y; Li Z; Xie Z
    Future Med Chem; 2017 Jun; 9(10):1087-1110. PubMed ID: 28632424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.
    Xiang Q; Pang X; Liu Z; Yang G; Tao W; Pei Q; Cui Y
    Pharmacol Ther; 2019 Nov; 203():107393. PubMed ID: 31356909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of platelet activation and development of antiplatelet agents].
    Cazenave JP; Gachet C; Lanza F
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of antiplatelet agents in sepsis: a glimpse into the future.
    Akinosoglou K; Alexopoulos D
    Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in antiplatelet therapy for ACS and PCI.
    Moliterno DJ
    J Interv Cardiol; 2008 Dec; 21 Suppl 1():S18-24. PubMed ID: 19090933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y
    Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G-protein-coupled receptors signaling pathways in new antiplatelet drug development.
    Gurbel PA; Kuliopulos A; Tantry US
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):500-12. PubMed ID: 25633316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
    Liu S; Li S; Yuan D; Wang E; Xie R; Zhang W; Kong Y; Zhu X
    Eur J Med Chem; 2021 Jan; 209():112893. PubMed ID: 33049608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
    Graff J; Klinkhardt U; Harder S
    Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 14-3-3zeta-GPIb-IX-V complex as an antiplatelet target.
    Andrews RK; Du X; Berndt MC
    Drug News Perspect; 2007 Jun; 20(5):285-92. PubMed ID: 17878956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk.
    Fuentes E; Palomo I
    Thromb Res; 2014 Aug; 134(2):221-6. PubMed ID: 24830902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives.
    Kalantzi KI; Tsoumani ME; Goudevenos IA; Tselepis AD
    Expert Rev Clin Pharmacol; 2012 May; 5(3):319-36. PubMed ID: 22697594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
    Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
    Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet agents.
    Varon D; Spectre G
    Hematology Am Soc Hematol Educ Program; 2009; ():267-72. PubMed ID: 20008209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Future Cardiol; 2015 Sep; 11(5):547-64. PubMed ID: 26406386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.